GENEVAX-HIV (APL 400-003) CANDIDATE DNA VACCINE--PILOT DOSE

此前的研究表明，一种成功的艾滋病毒疫苗需要 以诱导广泛的体液和细胞免疫反应。 具体地说，诱导1类MHC限制性细胞毒性T细胞 淋巴细胞和中和抗体反应可能针对A 病毒抗原的数量是设计的重要目标 第二代候选艾滋病疫苗。 这是第一项对HIV阴性志愿者进行安全性评估的研究， APL 400-003 HIV DNA疫苗的耐受性和免疫应答 Biojector 2000系统。 该项目的主要目的是确定是否有多个 肌肉注射Genevax HIV(APL 400-003)DNA质粒 剂量为100微克和300微克的疫苗可引发HIV-1 抗原特异性刺激HIV阴性免疫系统。另外， 以确定一种多方面的免疫反应是否具有 HIV特异性抗体、T辅助细胞和细胞毒T细胞的产生 淋巴细胞；在适当的条件下，它们可以保护 预防人类免疫缺陷病毒感染或推迟 疾病的发展。

Previous studies have suggested that a successful HIV vaccine will need to induce both broad humoral and cellular immune responses. Specifically, induction of class 1 MHC-restricted cytotoxic T lymphocytes and neutralizing antibody responses possibly against a number of viral antigens are important objectives in the design of second generation candidate AIDS vaccines. This is the first study in HIV-negative volunteers to evaluate safety, tolerance and immune response of APL 400-003 HIV DNA Vaccine using the Biojector 2000 system. The primary purpose of this project is to determine whether multiple intramuscular injections of the Genevax HIV (APL 400-003) DNA plasmid vaccine at dose levels of 100 ug and 300 ug can provoke an HIV-1 antigen-specific stimulation of the HIV negative immune system. Also, to determine if a multifaceted immune response characterized by production of HIV-specific antibodies, T helper cells and cytotoxic T lymphocytes; and which, under the appropriate conditions, may protect against infection by the Human Immunodeficiency Virus or delay the progression of disease.